Announcement of The Conolidated Financial Report for The 1st Quarter of 2022

2022.5.13

Provided by: TTY BIOPHARM COMPANY LIMITED
SEQ_NO 1 Date of announcement 2022/05/13 Time of announcement 17:55:48
Subject Announcement of The Conolidated Financial Report for The 1st Quarter of 2021
Date of events 2022/05/13 To which item it meets paragraph 31
Statement 1.Date of the financial reports submitted to the board of directors or approved by the board of directors:2022/05/13
2.Date of the financial reports approved by the audit committee:2022/05/13
3.Start and end dates of financial reports of the reporting period:2022/01/01~2022/03/31
4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):1,037,114
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):646,988
6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):246,556
7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):287,247
8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):227,941
9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):227,507
10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.91
11.Total assets end of the period (thousand NTD):9,269,538
12.Total liabilities end of the period (thousand NTD):3,220,092
13.Equity attributable to owners of parent end of the period (thousand NTD):5,452,702
14.Any other matters that need to be specified:None
TOP